Urigen's pipeline includes URG101, targeting the treatment of painful bladder syndrome (PBS), symptoms of pelvic bladder syndrome secondary to pelvic irradiation and dyspareunia.
View the product pipeline

Sep 12, 2012 - Urigen has signed a Commitment Letter regarding a term loan facitlity. Further information is available on SEC Edgar Online. Click here to view the PDF

Aug 10, 2012 - Urigen has filed the 2010 10-K. The filing is available on SEC Edgar Online.Click here to view the PDF

Jan 10, 2012, Walnut Creek, California - Urigen Update Click here to view the PDF

Jan 13, 2010, San Francisco, California - Prof. Lowell Parsons Presents Urigen at One Med Place Conference. Click here to view the slides

Oct 30, 2009, San Francisco, California - Urigen Overview of IC/Painful Bladder Syndrome for IC Awareness Week Click here. Click here to view the slides

May 29-Jun 3, 2010, San Francisco, California - Urigen will be attending the American Urological Association (AUA) 2010 Annual Meeting Click here.

Oct 1, 2012 - Decision in administrative proceeding regarding Urigen's Stock

Jun 5, 2012 - Suspension of trading in Urigen's stock

Oct 14, 2011 - Urigen Financing Update

Jul 1, 2011 - Urigen Development and Management Update

Mar 15, 2011 - Urigen announced a progress report, debt restructuring, a management update, and pipeline changes

Dec 15, 2010 - Urigen Announces Change in Management and FDA Update

Aug 18, 2010 - FDA Grants Urigen's URG101 Meeting

Aug 11, 2010 - Urigen Pharmaceuticals Announces FDA Follow Up

Jul 6, 2010 - Urigen FDA and Management Update

Apr 26, 2010 - Urigen Restructures Debt as Preferred Stock

Apr 23, 2010 - Urigen Files Request for FDA Meeting

Mar 18, 2010 - Urigen CEO Interview on Urigen.com

Mar 3, 2010 - Edward R. Teitel, MD, JD Becomes Chairman of Urigen

Jan 12 2009 - Urigen Pharmaceuticals Completes $257,000 Financing

Aug 19 2008 - Urigen Announces Issuance of Key Patent for URG101 - A Novel Therapy to Treat Painful Bladder Syndrome/Interstitial Cystitis

Apr 25 2008 - Urigen Announces US Patent Office Notice of Allowance of Claims for URG101

Mar 12 2008 - Urigen Announces Positive Phase II Clinical Trial Results with URG101


Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative products for urology indications. Urigen has two primary programs in development that are either in or positioned to enter Phase II clinical trials.